These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 11956125)

  • 1. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice.
    Burleigh ME; Babaev VR; Oates JA; Harris RC; Gautam S; Riendeau D; Marnett LJ; Morrow JD; Fazio S; Linton MF
    Circulation; 2002 Apr; 105(15):1816-23. PubMed ID: 11956125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoE-deficient and C57BL/6 mice.
    Burleigh ME; Babaev VR; Yancey PG; Major AS; McCaleb JL; Oates JA; Morrow JD; Fazio S; Linton MF
    J Mol Cell Cardiol; 2005 Sep; 39(3):443-52. PubMed ID: 16040051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis.
    Belton OA; Duffy A; Toomey S; Fitzgerald DJ
    Circulation; 2003 Dec; 108(24):3017-23. PubMed ID: 14638539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice.
    Praticò D; Tillmann C; Zhang ZB; Li H; FitzGerald GA
    Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3358-63. PubMed ID: 11248083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclooxygenase-2 and atherosclerosis.
    Linton MF; Fazio S
    Curr Opin Lipidol; 2002 Oct; 13(5):497-504. PubMed ID: 12352013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of cyclooxygenase with indomethacin phenethylamide reduces atherosclerosis in apoE-null mice.
    Burleigh ME; Babaev VR; Patel MB; Crews BC; Remmel RP; Morrow JD; Oates JA; Marnett LJ; Fazio S; Linton MF
    Biochem Pharmacol; 2005 Aug; 70(3):334-42. PubMed ID: 15950196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism.
    Egan KM; Wang M; Fries S; Lucitt MB; Zukas AM; Puré E; Lawson JA; FitzGerald GA
    Circulation; 2005 Jan; 111(3):334-42. PubMed ID: 15655126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids.
    Catella-Lawson F; McAdam B; Morrison BW; Kapoor S; Kujubu D; Antes L; Lasseter KC; Quan H; Gertz BJ; FitzGerald GA
    J Pharmacol Exp Ther; 1999 May; 289(2):735-41. PubMed ID: 10215647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
    Chan CC; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Ford-Hutchinson AW; Forrest MJ; Gauthier JY; Gordon R; Gresser M; Guay J; Kargman S; Kennedy B; Leblanc Y; Leger S; Mancini J; O'Neill GP; Ouellet M; Patrick D; Percival MD; Perrier H; Prasit P; Rodger I
    J Pharmacol Exp Ther; 1999 Aug; 290(2):551-60. PubMed ID: 10411562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of cyclooxygenase-derived prostaglandin E2 and nitric oxide in the protection of rat pancreas afforded by low dose of lipopolysaccharide.
    Jaworek J; Bonior J; Tomaszewska R; Jachimczak B; Kot M; Bielański W; Pawlik WW; Sendur R; Stachura J; Konturek PC; Konturek SJ
    J Physiol Pharmacol; 2001 Mar; 52(1):107-26. PubMed ID: 11321505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis.
    Belton O; Byrne D; Kearney D; Leahy A; Fitzgerald DJ
    Circulation; 2000 Aug; 102(8):840-5. PubMed ID: 10952950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in low density lipoprotein receptor-deficient mice.
    Babaev VR; Patel MB; Semenkovich CF; Fazio S; Linton MF
    J Biol Chem; 2000 Aug; 275(34):26293-9. PubMed ID: 10858435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-atherogenic effect of BHB-TZD having inhibitory activities on cyclooxygenase and 5-lipoxygenase in hyperlipidemic mice.
    Choi JH; Jeon HJ; Park JG; Sonn SK; Lee MR; Lee MN; You HJ; Kim GY; Kim JH; Lee MH; Kwon OS; Nam KH; Kim HC; Jeong TS; Lee WS; Oh GT
    Atherosclerosis; 2010 Sep; 212(1):146-52. PubMed ID: 20684827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of specific inhibition of cyclo-oxygenase-1 and cyclo-oxygenase-2 in the rat stomach with normal mucosa and after acid challenge.
    Gretzer B; Maricic N; Respondek M; Schuligoi R; Peskar BM
    Br J Pharmacol; 2001 Apr; 132(7):1565-73. PubMed ID: 11264251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid peroxidation and platelet activation in murine atherosclerosis.
    Cyrus T; Tang LX; Rokach J; FitzGerald GA; Praticò D
    Circulation; 2001 Oct; 104(16):1940-5. PubMed ID: 11602498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COX-2-derived prostacyclin confers atheroprotection on female mice.
    Egan KM; Lawson JA; Fries S; Koller B; Rader DJ; Smyth EM; Fitzgerald GA
    Science; 2004 Dec; 306(5703):1954-7. PubMed ID: 15550624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers.
    Van Hecken A; Schwartz JI; Depré M; De Lepeleire I; Dallob A; Tanaka W; Wynants K; Buntinx A; Arnout J; Wong PH; Ebel DL; Gertz BJ; De Schepper PJ
    J Clin Pharmacol; 2000 Oct; 40(10):1109-20. PubMed ID: 11028250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced atherosclerotic lesions in mice deficient for total or macrophage-specific expression of scavenger receptor-A.
    Babaev VR; Gleaves LA; Carter KJ; Suzuki H; Kodama T; Fazio S; Linton MF
    Arterioscler Thromb Vasc Biol; 2000 Dec; 20(12):2593-9. PubMed ID: 11116058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of COX-2 inhibitors on aortic prostacyclin production in cholesterol-fed rabbits.
    Wong E; Huang JQ; Tagari P; Riendeau D
    Atherosclerosis; 2001 Aug; 157(2):393-402. PubMed ID: 11472739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers.
    Brzozowski T; Konturek PC; Konturek SJ; Sliwowski Z; Pajdo R; Drozdowicz D; Ptak A; Hahn EG
    Microsc Res Tech; 2001 Jun; 53(5):343-53. PubMed ID: 11376495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.